F-1/A: NewGenIvf Files for Resale of 123 Million Shares Amidst Strategic Shifts

NewGenIvf Group Limited is registering the resale of up to 123,275,000 Class A Ordinary Shares by selling securityholders, following recent business developments and strategic realignments.

Summary

• NewGenIvf Group Limited has filed a registration statement for the resale of up to 123,275,000 Class A Ordinary Shares by its selling securityholders.
• The shares include those issued to Genetics & IVF Institute, A SPAC Holdings Group Corp, and those issuable to JAK Opportunities VI LLC and White Lion Capital, LLC upon conversion of notes and exercise of warrants.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders.
• NewGenIvf may receive up to $500 million from the sale of Class A Ordinary Shares to White Lion under a purchase agreement, and proceeds from the conversion of notes and warrants, which will be used for working capital and general corporate purposes.
• The company's Class A Ordinary Shares currently trade on The Nasdaq Global Market under the symbol NIVF, with the last reported closing price on April 29, 2025, at $0.31.
• NewGenIvf qualifies as a foreign private issuer and a controlled company, allowing it to rely on certain exemptions from Nasdaq corporate governance rules.
• The company terminated a term sheet for a proposed reverse merger with European Wellness Investment Holdings Limited (EWIHL) after EWIHL failed to provide required financial statements.
• NewGenIvf received an extension from Nasdaq to regain compliance with continued listing requirements, including a reverse stock split of 1-for-20 which was effected on February 11, 2025.
• The company regained compliance with the minimum bid price rule on February 27, 2025, and its application to transfer its listing to the Nasdaq Capital Market was approved.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential for significant capital infusion and regained Nasdaq compliance, there are also negative aspects such as the resale of shares potentially depressing the stock price and a recent net loss. The overall sentiment is neutral, reflecting a company in transition with both opportunities and challenges.

Positives

• The company regained compliance with the minimum bid price rule on February 27, 2025.
• The company's application to transfer its listing to the Nasdaq Capital Market was approved.
• The company has the potential to receive up to $500 million from the sale of shares to White Lion.
• The company has access to capital through the White Lion Purchase Agreement.

Negatives

• The resale of a large number of shares by selling securityholders could depress the market price of the company's Class A Ordinary Shares.
• The company terminated a proposed reverse merger with EWIHL due to unmet conditions.
• The company has a history of Nasdaq deficiency letters and required a reverse stock split to regain compliance.

Risks

• The sale of resale shares could depress the market price of the company's Class A Ordinary Shares.
• The company's ability to raise capital through the sale of additional equity securities could be impaired.
• Investing in the company's Class A Ordinary Shares involves a high degree of risk, including the risk of losing the entire investment.
• The company's businesses and operations are subject to the changing economic conditions prevailing from time to time in Thailand, Cambodia and Kyrgyzstan.

Future Outlook

NewGenIvf plans to offer broad fertility services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities, increase brand awareness and market share, and expand service reach through acquisitions and partnerships.

Industry Context

The document highlights the increasing demand for assisted reproductive services (ARS) in the Asia-Pacific region, driven by factors such as rising infertility rates, later maternal age, and increasing social acceptance of ARS. NewGenIvf aims to capitalize on this growing market by offering comprehensive fertility treatment services and expanding its reach through strategic acquisitions and partnerships.

Comparison to Industry Standards

• The document mentions that the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication).
• The document mentions that PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.

Management Changes

Corporate Governance

Stakeholder Impact

• The resale of a large number of shares by selling securityholders could depress the market price of the company's Class A Ordinary Shares, negatively impacting shareholders.
• The company's ability to raise capital through the sale of additional equity securities could be impaired, potentially affecting its ability to invest in growth initiatives.
• The company's businesses and operations are subject to the changing economic conditions prevailing from time to time in Thailand, Cambodia and Kyrgyzstan, potentially impacting employees and suppliers.

Next Steps

• The Selling Securityholders may offer all or part of the securities for resale from time to time through public or private transactions.
• The company may elect to sell Class A Ordinary Shares to White Lion pursuant to the White Lion Purchase Agreement.
• The company will use proceeds from conversion of notes and sales of Class A Ordinary Shares to White Lion for working capital and other general corporate purposes.

Key Dates

Keywords

Class A Ordinary Shares, Resale, NewGenIvf, Warrants, Convertible Notes, Nasdaq, White Lion, MicroSort, EWIHL, Listing Requirements, Reverse Stock Split, Securities Purchase Agreement, Registration Statement, Selling Securityholders, Compliance